ACTU vs PRAX vs JPM vs KALA vs CRL

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Actuate Therapeutics Inc (ACTU) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, JPMorgan Chase & Co.

is actually cheaper at 14. 4x.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: JPM returned +465. 8% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Actuate Therapeutics Inc's 2. 21β — meaning ACTU is approximately 135% more volatile than JPM relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Actuate Therapeutics Inc grew EPS 67. 5% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 0. 0% for KALA. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 16. 9x for Charles River Laboratories International, Inc. — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACTU: 939. 6% to $21. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. ACTU, PRAX, KALA, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). KALA BIO, Inc. (KALA) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACTU (Healthcare) and PRAX (Healthcare) and JPM (Financial Services) and KALA (Healthcare) and CRL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACTU is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; KALA is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock. JPM pays a dividend while ACTU, PRAX, KALA, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.